Publications by authors named "Gregory Masters"

Claim this Profile
P
Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538.
Michael K Farris, Michael D Mix, Xiaofei Wang, Brandy Jaszewski, Nathan Foster, Gregory A Masters

JAMA Netw Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Gregory Masters

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Gregory Masters

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus statement and clinical pathway for the management of colon cancer with peritoneal metastases in the state of Delaware.
Jesus Esquivel, Nicholas Petrelli, James Spellman, Joseph Bennett, Suguna Chirla, Gregory Masters

Surg Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.
Joanne B Weidhaas, Chen Hu, Ritsuko Komaki, Gregory A Masters, George R Blumenschein

Cancer Res Commun· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2.
Dwight H Owen, Navneet Singh, Nofisat Ismaila, Gregory Masters, Gregory J Riely

J Clin Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Benjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson, Laura E Lamb, Marc Matrana, Gregory A Masters

Cancer Res Commun· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki

J Clin Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2.
Dwight H Owen, Navneet Singh, Nofisat Ismaila, Elizabeth Blanchard, Paul Celano, Gregory Masters

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2.
Dwight H Owen, Navneet Singh, Nofisat Ismaila, Elizabeth Blanchard, Paul Celano, Gregory Masters

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Scott A Tomlins, Nickolay A Khazanov, Benjamin J Bulen, Daniel H Hovelson, Melissa J Shreve, Gregory Masters

Commun Med (Lond)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181.
John Michael Varlotto, Zhuoxin Sun, Bonnie Ky, Jenica Upshaw, Thomas J Fitzgerald, Gregory Masters

Clin Lung Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
Navneet Singh, Sarah Temin, Sherman Baker, Elizabeth Blanchard, Julie R Brahmer, Gregory Masters

J Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Navneet Singh, Sarah Temin, Sherman Baker, Elizabeth Blanchard, Julie R Brahmer, Gregory Masters

J Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attention to diet, exercise, and weight in oncology care: Results of an American Society of Clinical Oncology national patient survey.
Jennifer A Ligibel, Lori J Pierce, Catherine M Bender, Tracy E Crane, Christina Dieli-Conwright, Gregory A Masters

Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
John M Varlotto, Zhuoxin Sun, Bonnie Ky, Jenica Upshaw, Sharyn I Katz, Gregory Masters

Oncologist· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
Jeffrey A Bogart, Xiaofei Wang, Gregory A Masters, Junheng Gao, Ritsuko Komaki

Lung Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Jill Brufsky, Laura C Cappelli, Gregory A Masters

J Immunother Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice.
Filippo Veglia, Ayumi Hashimoto, Harsh Dweep, Emilio Sanseviero, Alessandra De Leo, Gregory Masters

J Exp Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker, Julie R Brahmer, Gregory Masters

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway.
Kevin Alicea-Torres, Emilio Sanseviero, Jun Gui, Jinyun Chen, Filippo Veglia, Gregory Masters

Nat Commun· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer.
Taekyoung Kwak, Fang Wang, Hui Deng, Thomas Condamine, Vinit Kumar, Gregory Masters

Cell Rep· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Summary.
Nasser H Hanna, Sarah Temin, Gregory Masters

JCO Oncol Pract· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Bryan J Schneider, Sarah Temin, Sherman Baker, Julie Brahmer, Gregory Masters

J Clin Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Jeffrey D Bradley, Chen Hu, Ritsuko R Komaki, Gregory A Masters, George R Blumenschein

J Clin Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis